Balstilimab + Botensilimab + Liposomal Doxorubicin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed Glioblastoma
Conditions
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
Trial Timeline
Jan 31, 2024 → Aug 1, 2026
NCT ID
NCT05864534About Balstilimab + Botensilimab + Liposomal Doxorubicin
Balstilimab + Botensilimab + Liposomal Doxorubicin is a phase 2 stage product being developed by Agenus for Newly Diagnosed Glioblastoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05864534. Target conditions include Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05864534 | Phase 2 | Recruiting |
Competing Products
18 competing products in Newly Diagnosed Glioblastoma